on Drägerwerk AG & Co. KGaA (ETR:DRW8)
Drägerwerk AG & Co. KGaA Reports Strong Q3 2025 Results
Lübeck-based Drägerwerk AG & Co. KGaA announced significant gains in net sales and earnings for Q3 2025. Preliminary figures reveal a net sales increase of 10.1% to approximately EUR 833 million, marking a recovery for both its medical and safety divisions. The medical division posted a 10.2% growth, reaching EUR 471 million, while the safety division reported a 9.9% increase to EUR 362 million.
Earnings before interest and taxes (EBIT) surged, more than doubling to around EUR 57 million. This improvement was driven by substantial sales growth and moderate cost rises, leading to an EBIT margin increase of 3.7 percentage points to 6.8%.
Order intake increased by 6.9% to EUR 856 million. The medical division saw a 5.4% rise, with the safety division experiencing an 8.8% growth. The company anticipates its full-year net sales and EBIT margin to be in the upper half of the forecast range.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Drägerwerk AG & Co. KGaA news